信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

VOLUNTARY ANNOUNCEMENT
THE APPROVAL OF BEVAGEN® (BEVACIZUMAB BIOSIMILAR) BY THE INDONEDIAN FOOD AND DRUGS AUTHORITY

This announcement is made by Innovent Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Indonesian Food and Drugs Authority has approved Bevagen® (bevacizumab biosimilar), a recombinant humanized anti-vascular endothelial growth factor ("**VEGF**") monoclonal antibody drug, for the treatment of five indications, including metastatic colorectal cancer, locally recurrent or metastatic triple negative breast cancer, advanced, metastatic, or recurrent non-small cell lung cancer, epithelial ovarian, fallopian tube, and primary peritoneal cancer, and cervical cancer. PT Etana Biotechnologies Indonesia ("**Etana**") will commercialize Bevagen® (bevacizumab biosimilar) in Indonesia under the current licensing agreement with the Company. Bevagen® will potentially be the first Chinese antibody drug to be marketed and locally produced in Southeast Asia.

According to GLOBOCAN 2020 data, the highest cancer incidence rate in Indonesia are breast cancer (16.6%), cervical cancer (9.2%), lung cancer (8.8%), liver cancer (5.4%) and colorectal cancer (4.4%). The approval of Bevagen® (bevacizumab biosimilar) in Indonesia marked a meaningful step towards bringing the Company's innovative portfolio into the global market, benefitting patients globally. Pairing Etana's commercial expertise in the local Indonesian market with Bevagen® (bevacizumab biosimilar)'s clinical profile, high-quality production and relative affordability, the Company is confident that Bevagen® (bevacizumab biosimilar) will be launched to the market quickly and will benefit many cancer patients.

About Bevagen® (Bevacizumab Biosimilar)

Bevagen® is a biosimilar of the recombinant humanized anti-VEGF monoclonal antibody bevacizumab. Vascular endothelial growth factor (VEGF) is a critical factor in promoting angiogenesis, and is highly expressed by the endothelial cells in most tumors. An anti-VEGF antibody selectively binds to VEGF , preventing their binding to VEGF receptors on the surface of vascular endothelial cells, thereby inhibiting key signaling pathways, such as PI3K-Akt/PKB and Ras-Raf-MEK-ERK, and producing anti-tumor effects. Since its launch, bevacizumab has been approved for the treatment of patients with multiple malignant tumors globally, including non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The efficacy and safety of bevacizumab have been well documented and recognized worldwide.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
June 14, 2022

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.